Carotegrast methyl free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 597778

CAS#: 401905-67-7 (free base)

Description: Carotegrast methyl, also known as AJM300, is an orally-active small molecule that antagonises the α4 integrin receptor. AJM300 reduces inflammation by blocking leucocyte trafficking. This study aimed to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of AJM300 in healthy male subjects. AJM300 is in development for the treatment of active ulcerative colitis. AJM300 was well tolerated and more effective than placebo in inducing clinical response, clinical remission, and mucosal healing in patients with moderately active UC.

Chemical Structure

Carotegrast methyl free base
CAS# 401905-67-7 (free base)

Theoretical Analysis

MedKoo Cat#: 597778
Name: Carotegrast methyl free base
CAS#: 401905-67-7 (free base)
Chemical Formula: C28H26Cl2N4O5
Exact Mass: 568.128
Molecular Weight: 569.43
Elemental Analysis: C, 59.06; H, 4.60; Cl, 12.45; N, 9.84; O, 14.05

Price and Availability

Size Price Availability Quantity
10.0mg USD 450.0 2 Weeks
25.0mg USD 750.0 2 Weeks
50.0mg USD 1250.0 2 Weeks
100.0mg USD 1950.0 2 Weeks
200.0mg USD 2950.0 2 Weeks
Bulk inquiry

Related CAS #: 1338380-51-0 (mesylate)   401905-67-7 (free base)   1338380-52-1 (HCl)   1338380-53-2 (HBr)   1338380-56-5 (tosylate)    

Synonym: Carotegrast methyl; AJM300; AJM-300; AJM 300;

IUPAC/Chemical Name: methyl (S)-2-(2,6-dichlorobenzamido)-3-(4-(6-(dimethylamino)-1-methyl-2,4-dioxo-1,4-dihydroquinazolin-3(2H)-yl)phenyl)propanoate


InChi Code: InChI=1S/C28H26Cl2N4O5/c1-32(2)18-12-13-23-19(15-18)26(36)34(28(38)33(23)3)17-10-8-16(9-11-17)14-22(27(37)39-4)31-25(35)24-20(29)6-5-7-21(24)30/h5-13,15,22H,14H2,1-4H3,(H,31,35)/t22-/m0/s1

SMILES Code: O=C(OC)[C@H](CC1=CC=C(N2C(N(C)C3=C(C=C(N(C)C)C=C3)C2=O)=O)C=C1)NC(C4=C(Cl)C=CC=C4Cl)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 569.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Gubatan J, Keyashian K, Rubin SJS, Wang J, Buckman CA, Sinha S. Anti- Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives. Clin Exp Gastroenterol. 2021 Aug 24;14:333-342. doi: 10.2147/CEG.S293272. PMID: 34466013; PMCID: PMC8402953.

2: Solitano V, Parigi TL, Ragaini E, Danese S. Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents. Expert Opin Investig Drugs. 2021 Oct;30(10):1037-1046. doi: 10.1080/13543784.2021.1974396. Epub 2021 Sep 6. PMID: 34449288.

3: Misselwitz B, Juillerat P, Sulz MC, Siegmund B, Brand S; Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More. Digestion. 2020;101 Suppl 1:69-82. doi: 10.1159/000507782. Epub 2020 Jun 22. PMID: 32570252.

4: Lucaciu LA, Seicean R, Seicean A. Small molecule drugs in the treatment of inflammatory bowel diseases: which one, when and why? - a systematic review. Eur J Gastroenterol Hepatol. 2020 Jun;32(6):669-677. doi: 10.1097/MEG.0000000000001730. PMID: 32282548.

5: Fukase H, Kajioka T, Oikawa I, Ikeda N, Furuie H. Food Effect on a Single High Dose of Carotegrast Methyl, an Oral Antagonist of α4-Integrin, in Healthy Male Subjects: A Randomised, Placebo-Controlled, Double-Blind Study. Clin Drug Investig. 2020 Mar;40(3):237-247. doi: 10.1007/s40261-019-00879-1. PMID: 31965548; PMCID: PMC7035301.

6: Fukase H, Kajioka T, Oikawa I, Ikeda N, Furuie H. AJM300, a novel oral antagonist of α4-integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects. Br J Clin Pharmacol. 2020 Mar;86(3):591-600. doi: 10.1111/bcp.14151. Epub 2020 Jan 28. PMID: 31658381; PMCID: PMC7080631.

7: Shukla T, Sands BE. Novel Non-biologic Targets for Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2019 Apr 23;21(5):22. doi: 10.1007/s11894-019-0689-2. PMID: 31016396.

8: Li H, Huang SY, Shi FH, Gu ZC, Zhang SG, Wei JF. α4β7 integrin inhibitors: a patent review. Expert Opin Ther Pat. 2018 Dec;28(12):903-917. doi: 10.1080/13543776.2018.1549227. Epub 2018 Nov 22. PMID: 30444683.

9: Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Bamias G, Dulai PS, Boland BS, Sandborn WJ, Patel DR, Rivera-Nieves J. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. Inflamm Bowel Dis. 2019 Jan 10;25(2):270-282. doi: 10.1093/ibd/izy269. PMID: 30165490; PMCID: PMC6327230.

10: Park SC, Jeen YT. Anti-integrin therapy for inflammatory bowel disease. World J Gastroenterol. 2018 May 7;24(17):1868-1880. doi: 10.3748/wjg.v24.i17.1868. PMID: 29740202; PMCID: PMC5937204.

11: White JR, Phillips F, Monaghan T, Fateen W, Samuel S, Ghosh S, Moran GW. Review article: novel oral-targeted therapies in inflammatory bowel disease. Aliment Pharmacol Ther. 2018 Jun;47(12):1610-1622. doi: 10.1111/apt.14669. Epub 2018 Apr 19. PMID: 29672874.

12: Vetter M, Neurath MF. Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges. Therap Adv Gastroenterol. 2017 Oct;10(10):773-790. doi: 10.1177/1756283X17727388. Epub 2017 Sep 5. PMID: 29051788; PMCID: PMC5638182.

13: Coskun M, Vermeire S, Nielsen OH. Novel Targeted Therapies for Inflammatory Bowel Disease. Trends Pharmacol Sci. 2017 Feb;38(2):127-142. doi: 10.1016/ Epub 2016 Dec 1. PMID: 27916280.

14: Naganuma M, Mizuno S, Nanki K, Sugimoto S, Kanai T. Recent trends and future directions for the medical treatment of ulcerative colitis. Clin J Gastroenterol. 2016 Dec;9(6):329-336. doi: 10.1007/s12328-016-0686-z. Epub 2016 Oct 3. PMID: 27699641.

15: Nielsen OH, Seidelin JB, Ainsworth M, Coskun M. Will novel oral formulations change the management of inflammatory bowel disease? Expert Opin Investig Drugs. 2016 Jun;25(6):709-18. doi: 10.1517/13543784.2016.1165204. Epub 2016 Mar 28. PMID: 26967267.

16: McLean LP, Cross RK. Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease. Expert Opin Investig Drugs. 2016;25(3):263-73. doi: 10.1517/13543784.2016.1148137. PMID: 26822204; PMCID: PMC4926164.

17: Yoshimura N, Watanabe M, Motoya S, Tominaga K, Matsuoka K, Iwakiri R, Watanabe K, Hibi T; AJM300 Study Group. Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis. Gastroenterology. 2015 Dec;149(7):1775-1783.e2. doi: 10.1053/j.gastro.2015.08.044. Epub 2015 Aug 29. PMID: 26327130.

18: Danese S, Panés J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology. 2014 Nov;147(5):981-9. doi: 10.1053/j.gastro.2014.08.044. Epub 2014 Sep 16. PMID: 25220794.

19: Saruta M, Papadakis KA. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases. Gastroenterol Clin North Am. 2014 Sep;43(3):581-601. doi: 10.1016/j.gtc.2014.05.012. Epub 2014 Jun 25. PMID: 25110260.

20: Halland N, Blum H, Buning C, Kohlmann M, Lindenschmidt A. Small Macrocycles As Highly Active Integrin α2β1 Antagonists. ACS Med Chem Lett. 2014 Jan 10;5(2):193-8. doi: 10.1021/ml4004556. PMID: 24900800; PMCID: PMC4027761.